Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1389-1397

  Stapleton, Alan M F ^a   Timme, Terry L ^a   Gousse, Angelo E ^a   Li, Qi Fu ^a   Tobon, Andrew A ^a   Kattan, Michael W ^a   Slawin, Kevin M ^a   Wheeler, Thomas M ^a   Scardino, Peter T ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; DNA, NEOPLASM; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; POINT MUTATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030754058     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 46: 5-27, 1996.
2. Sakr, W. A., Macoska, J. A., Benson, P., Grignon, D. J., Wolman, S. R., Pontes, J. E., and Crissman, J. D. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res., 54: 3273-3277, 1994.
3. Qian, J., Bostwick, D., Takashi, S., Borell, T., Herath, J., Lieber, M., and Jenkins, R. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res., 55: 5408-5414, 1995.
4. Miller, G. J., and Cygan, J. M. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume, and capsular penetration. J. Urol., 152: 1709-1713, 1994.
5. Mirchandani, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K., Cote, R. J., and Roy-Burman, R. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am. J. Pathol., 147: 92-101, 1995.
6. Konishi, N., Hiasa, Y., Matsuda, H., Tao, M., Tsuzuki, T., Hayashi, I., Kitahori, Y., Shiraishi, T., Yatani, R., Shimazaki, J., and Lin, J-C. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am. J. Pathol., 147: 1112-1122, 1995.
7. Thompson, T. C., Timme, T. L., Park, S. H., Ren, C., Baley, P. A., Eastham, J. A., Sehgal, I., Yang, G., and Kadmon, D. Tissue and cell-cell interactions in prostate cancer progression. Cancer (Phila.), 75: 1885-1891, 1995.
8. Thompson, T. C., Park, S. H., Timme, T. L., Ren, C. Eastham, J. A., Donehower, L. A., Bradley, A., Kadmon, D., and Yang, G. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene, 10: 869-879, 1995.
9. Navone, N., Troncoso, P., Pisters, L., Goodran, T., Palmer, J., Nichols, W., von Eschenbach, A., and Conti, C. p53 accumulation and gene mutation in the progression of human prostate cancer. J. Natl. Cancer Inst., 85: 1657-1669, 1993.
10. Chi, S. G., deVere White, R. W., Meyers, F. J., Siders, D. B., Lee, F., and Gumerlock, P. H. p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst., 86: 926-933, 1994.
11. Eastham, J. A., Stapleton, A. M. F., Gousse, A., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Association of p53 mutations with metastatic prostate cancers. Clin. Cancer Res., 1; 1111-1118, 1995.
12. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W., and Srivastava, S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol., 154: 414-421, 1995.
13. Hughes, J. H., Cohen, M. B., and Robinson, R. A. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma. Mod. Pathol., 8: 462-466, 1995.
14. Schroeder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer. Prostate, 4: 129-138, 1992.
15. Gleason, D. F. Histologic grading of prostate cancer: a perspective. Hum. Pathol., 23: 273-279, 1992.
16. Meyers, F. J., Chi, S. G., Fishman, J. R., deVere White, R. W., and Gumerlock, P. H. p53 mutations in benign prostatic hyperplasia. J. Natl. Cancer Inst., 85: 1856-1858, 1993.
17. Yang, G., Stapleton, A. M. F., Wheeler, T. M., Truong, L. D., Timme, T. L., Scardino, P. T., and Thompson, T. C. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin. Cancer Res., 2: 635-640, 1996.
18. Orita, M., Susuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 39: 874-879, 1989.
19. Conover, W. J. Practical Nonparametric Statistics, 2nd. ed. New York: John Wiley & Sons, Inc., 1980.
20. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, B., and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.
21. Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA, 87: 7555-7559, 1990.
22. Voeller, H. J., Sugars, L. Y., Pretlow, T., and Gelmann, E. P. p53 oncogene mutations in human prostate cancer specimens. J. Urol., 151: 492-495, 1994.
23. Bauer, J. J., Sesterhenn, I. A., Mostofi, K. F., McLeod, D. G., Srivastava, S., and Moul, J. W. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1: 1295-1300, 1995.
24. Shurbaji, M. S., Kalbfleisch, J. H., and Thurmond, T. S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Pathol., 26: 106-109, 1995.
25. Stricker, H. J., Jay, J. K., Linden, M. D., Tamboli, P., and Amin, M. B. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology. 47: 366-369, 1996.
26. Effert, P. J., Neubauer, A., Walther, P. J., and Liu, E. T. Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J. Urol., 147: 789-793, 1992.
27. Dinjens, W. N. M., van der Weiden, M. M., Schroeder, F. H., Bosman, F. T., and Trapman, J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Br. J. Cancer, 56: 630-633, 1994.
28. Sameshima, Y., Akiyama, T., Mori, N., Mizoguchi, H., Toyoshima, K., Sugimura, T., Terada, M., and Yokota, J. Point mutation of the p53 gene resulting in splicing inhibition in small cell carcinoma. Biochem. Biophys. Res. Commun., 173: 697-703, 1990.
29. Chiba, I., Takahasi, T., Nau, M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piamadosi, S., Koga, H., Reissman, P. T., Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.
30. Soudon, J., Caron de Fromentel, C., Bernard, O., and Larsen, C-J. Inactivation of the p53 gene expression by a splice donor site mutation in a human T-cell leukemia cell line. Leukemia (Baltimore), 5: 917-920, 1991.
31. Foti, A., Bar-Eli, M., Ahuja, H. G., and Cline, M. J. A splicing mutation accounts for the lack of p53 gene expression by a CML blast crisis cell line: a novel mechanism of p53 gene inactivation. Br. J. Haematol., 76: 143-145, 1990.
32. Lozano, G., and Levine, A. J. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol. Carcinog., 4: 3-9, 1991.
33. Cha, R. S., and Thilly, W. G. Specificity, efficiency, and fidelity of PCR. PCR Methods Appl., 3: S18-S29, 1993.
34. Eckert, K. A., and Kunkel, T. A. DNA polymerase fidelity and the polymerase chain reaction. PCR Methods Appl., 1: 17-24, 1991.
35. Moyret-Lalle, C., Marcais, C., Jacquemier, J., Moles, J. P., Daver, A., Soret, J. Y., Jeanteur, P., Ozturk, M., and Theillet, C. ras, p53, and HPV status in benign and malignant prostate tumors. Int. J. Cancer, 64: 124-129, 1995.
36. Sidransky, D., von Eschenbach, A. C., Tsai, Y. C., Jones, P. A., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., and Vogelstein, B. Identification of p53 gene mutations in bladder cancers and urine samples. Science (Washington DC), 252: 706-709, 1991.
37. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
38. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
39. Ueba, T., Nosaka, T., Takahashi, J., Shibata, F., Florkiewicz, R., Vogelstein, B., Oda, Y., Kikuchi, H., and Hatanaka, M. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA, 91: 9009-9013, 1994.
40. Dameron, K., Volpert, O., Tainsky, M., and Bouck, N. Control of ansiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
41. Kieser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
42. Aihara, M., Scardino, P. T., Truong, L. D., Wheeler, T. M., Goad, J. R., Yang, G., and Thompson, T. C. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer (Phila.), 75: 522-529, 1995.
43. Harriss, D. R., and Savill, J. Apoptosis and the prostate. Br. J. Urol., 75: 27-33, 1995.
44. Thompson, T. C., Timme, T. L., and Sehgal, I. The role of p53 in prostate cancer progression. In: J. G. Fortner and P. A. Sharp (eds.), Accomplishments in Cancer Research 1996. in press. Philadelphia: Lippincott-Raven, 1997.
45. Thompson, T. C., Timme, T. L., and Sehgal, I. Oncogenes. growth factors, and hormones in prostate cancer. In: R. B. Dickson and D. S. Salomon (eds.), Hormones and Growth Factors in Development and Neoplasia, in press. New York: John Wiley & Sons. Inc., 1997.